Protease Inhibitor

ApprovedSmall molecule

MMedical Research Council

Protease Inhibitor is one of 75 small molecule programs targeting HIV infection. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV InfectionActive, not recruiting

AtrophyActive, not recruiting

HIV InfectionApproved

Active, not recruiting

AtrophyApproved

Active, not recruiting

Competition

Competitive Landscape

326 competitors in HIV Infection

#DrugCompanyPhaseTrials

Leukine

Sanofi

Phase 3

2 2

Sunlenca

Gilead

Phase 3

1 3

Hivid

CConrado Roberto Hoffmann Filho

Phase 3

9 4

Praluent

Regeneron

Phase 3

1 5

Megace

Bristol-Myers Squibb

Phase 3

—6

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

2 7

Foscavir

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 3

1 8

Buprenorphine/naloxone

Astellas

Phase 3

1 9

F/TAF

Gilead

Phase 3

1 10

PTM SEMA

Gilead

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Viremia1 trial

Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)

Terminated·AANRS, Emerging Infectious Diseases·Phase 3·NCT02247687·4 enrolled

HIV infection1 trial

Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)

Unknown status·MMedical Research Council·Phase 4·NCT01230580·587 enrolled

Atrophy1 trial

Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 4·NCT00122668·112 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Protease Inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Protease Inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Protease Inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical Research Council company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMedical Research Council

Protease Inhibitor

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Viremia1 trial

HIV infection1 trial

Atrophy1 trial

References

Drug Info

Quick Facts

Related News